PureTech Health (LON:PRTC) Trading 14.2% Higher - Here's Why

Key Points

• PureTech Health plc shares surged by 14.2% to a high of GBX 123.80 ($1.67) amid significant trading activity, with over 9 million shares exchanged—an increase of 1,053% compared to the average volume.
• The company has a market capitalization of £293.65 million and maintains a high PE ratio of 714.71, indicating its stock is valued highly relative to its earnings.
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1, reflecting insider confidence in the company as they hold 13.13% of its stock.

PureTech Health plc (LON:PRTC - ) shares were up 14.2% during trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares traded hands during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Performance

The firm has a market cap of £293.65 million, a PE ratio of 714.71 and a beta of 1.02. The firm has a 50-day moving average price of GBX 129.46 and a two-hundred day moving average price of GBX 129.83. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.

Insider Buying and Selling

In related news, insider Bharatt Chowrira acquired 167,739 shares of PureTech Health stock in a transaction that occurred on Thursday, July 3rd. The shares were purchased at an average price of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company's stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.